Gri Bio, Inc. (GRI) intrinsic value & 10-year financials
Gri Bio, Inc. (GRI) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.38
- Market cap
- $135.5K
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -254.6%
- Free cash flow (FY2025)
- -$10.2M
GRI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$12.0M | -$121.80 | -$10.2M | — | 765.1% |
| FY2024 | — | -$8.2M | -$55.21 | -$8.6M | — | 665.7% |
| FY2023 | — | -$13.0M | -$28.25 | -$9.0M | — | 876.7% |
| FY2022 | — | -$7.0M | -$0.69 | -$7.1M | — | -1841.2% |
| FY2021 | $0 | -$9.3M | -$1.42 | -$8.3M | — | -2340.4% |
| FY2020 | $100.0K | -$4.8M | -$1.07 | -$3.7M | -4788.0% | 346.2% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
GRI Bio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
GRI Bio, Inc. has historically struggled to out-earn its cost of capital, averaging just -2.5% ROIC.
GRI Bio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
GRI Bio, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.